Selected article for: "amino acid and SARS epidemic"
Author: Anirudhan, Varada; Lee, Hyun; Cheng, Han; Cooper, Laura; Rong, Lijun
Title: Targeting SARS‐CoV‐2 viral proteases as a therapeutic strategy to treat COVID‐19
  • Cord-id: 1rircrrk
  • Document date: 2021_2_9
    • ID: 1rircrrk
    Snippet: The 21st century has witnessed three outbreaks of coronavirus (CoVs) infections caused by severe acute respiratory syndrome (SARS)‐CoV, Middle East respiratory syndrome (MERS)‐CoV, and SARS‐CoV‐2. Coronavirus disease 2019 (COVID‐19), caused by SARS‐CoV‐2, spreads rapidly and since the discovery of the first COVID‐19 infection in December 2019, has caused 1.2 million deaths worldwide and 226,777 deaths in the United States alone. The high amino acid similarity between SARS‐CoV a
    Document: The 21st century has witnessed three outbreaks of coronavirus (CoVs) infections caused by severe acute respiratory syndrome (SARS)‐CoV, Middle East respiratory syndrome (MERS)‐CoV, and SARS‐CoV‐2. Coronavirus disease 2019 (COVID‐19), caused by SARS‐CoV‐2, spreads rapidly and since the discovery of the first COVID‐19 infection in December 2019, has caused 1.2 million deaths worldwide and 226,777 deaths in the United States alone. The high amino acid similarity between SARS‐CoV and SARS‐CoV‐2 viral proteins supports testing therapeutic molecules that were designed to treat SARS infections during the 2003 epidemic. In this review, we provide information on possible COVID‐19 treatment strategies that act via inhibition of the two essential proteins of the virus, 3C‐like protease (3CL(pro)) or papain‐like protease (PL(pro)).

    Search related documents:
    Co phrase search for related documents
    • acceptor inhibitor and acute respiratory syndrome: 1, 2, 3, 4
    • acquire infection and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
    • active site region and acute respiratory syndrome: 1, 2, 3
    • activity assessment and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7
    • activity profiling and acute respiratory syndrome: 1, 2, 3, 4, 5, 6
    • acute respiratory syndrome and additional factor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute respiratory syndrome and low oral bioavailability: 1, 2, 3
    • acute respiratory syndrome and lung proinflammatory storm: 1
    • acute respiratory syndrome and lxgg motif: 1, 2